Clinical Trials

27 Sep 2019
- Clinical Trials
- Human Trials
Noveome Biotherapeutics initiates trial evaluating intranasal delivery of ST266 targeting optic nerve and brain

By PBR Staff Writer

Noveome Biotherapeutics, a clinical-stage biopharmaceutical company focused on developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or damaged tissues, announced initiation of a Phase 1 open label clinical trial to establish the safety of ST266 when delivered intranasally in patients diagnosed with intraocular hypertension who have not yet developed optic nerve damage.
26 Sep 2019
Clinical Trials
Human Trials
Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo

By PBR Staff Writer

Incyte announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult patients (age ≥12 years) with vitiligo.
26 Sep 2019
Clinical Trials
Human Trials
Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy trial

By PBR Staff Writer

Jazz Pharmaceuticals announced that its JZP-258 investigational medicine has met primary and key secondary endpoints in phase 3 narcolepsy trial.
25 Sep 2019
Clinical Trials
Human Trials
Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia

By PBR Staff Writer

Zealand Pharma announced that its dasiglucagon has met primary and all major secondary endpoints in paediatric phase 3 trial of severe hypoglycaemia.
24 Sep 2019
Clinical Trials
Human Trials
Ipsen announces positive results from ENGAGE study of Dysport combo with GSC in adults with upper and lower limb spastic hemiparesis

By PBR Staff Writer

Ipsen announced first results from the ENGAGE study which reports that simultaneous treatment with Dysport of both upper and lower limb spasticity in adult patients along with a Guided Self-rehabilitation Contract (GSC) – a personalized diary-based rehabilitation program – improved patients’ voluntary movement as measured by a composite active range of motion (CXA) outcome.
24 Sep 2019
Clinical Trials
Human Trials
Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals

By PBR Staff Writer

Clovis Oncology has entered into a global licensing and collaboration agreement with 3B Pharmaceuticals GmbH (3BP), a private German biotechnology company developing targeted radiopharmaceutical drugs and diagnostics for oncology indications with a high unmet medical need.
24 Sep 2019
Clinical Trials
Human Trials
Cerevel’s tavapadon meets primary endpoint in phase 2 trial in Parkinson’s disease

By PBR Staff Writer

Cerevel Therapeutics said that a phase 2 trial assessing orally-administered tavapadon (formerly PF-06649751) in patients with early-stage Parkinson’s disease has met its primary endpoint.
19 Sep 2019
Clinical Trials
Human Trials
Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion

By PBR Staff Writer

Graybug Vision, a clinical stage pharmaceutical company developing potentially transformative long-acting therapies for ocular diseases including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), retinal vein occlusion (RVO), and primary open angle glaucoma (POAG), announced the initiation of its Phase 2a study with GB-102 in patients with macular edema (ME) secondary to DME or RVO.
19 Sep 2019
Clinical Trials
Human Trials
Novartis’ Cosentyx meets primary endpoint at Week 16 in PREVENT trial

By PBR Staff Writer

Novartis said that the phase 3 trial of its psoriasis drug Cosentyx (secukinumab), called PREVENT, in patients with non-radiographic axial spondyloarthritis (nr-axSpA), has met its primary endpoint at Week 16.
18 Sep 2019
Clinical Trials
Human Trials
Concert Pharmaceuticals completes enrollment in second open label trial of CTP-543 in alopecia areata

By PBR Staff Writer

Concert Pharmaceuticals announced that it has completed patient enrollment of an open label clinical trial to evaluate once-daily 24 mg compared to twice-daily 12 mg oral dosing of CTP-543 in patients with alopecia areata.

Drug Discovery

Research & Development

Sciwind secures China’s NMPA approval for Ecnoglutide injection

J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma

Clinical Trials

Patient Enrollment

US FDA approves Avacta Group’s IND application for AVA6000

AM-Pharma enrols first patients in Covid-19 phase III trial

Regulation

Drug Filing

Viatris files applications in Japan for approval of Effexor to treat GAD

Scholar Rock submits application of SMA therapy to FDA

Production & Sales

Manufacturing

ENCell and Lucy Biotech forge alliance for mesenchymal stem cell therapy

Merck introduces single-use reactor to accelerate ADC manufacturing

Packaging & Supply Chain

Packaging

Gerresheimer at CPHI Frankfurt 2025

Gerresheimer

Suppliers

No data found

Clinical Trials

Noveome Biotherapeutics initiates trial evaluating intranasal delivery of ST266 targeting optic nerve and brain

Incyte announces first patient treated in phase 3 trial program evaluating Ruxolitinib cream in patients with vitiligo

Jazz’s JZP-258 investigational medicine meets key end points in phase 3 narcolepsy trial

Zealand’s dasiglucagon meets key endpoints in paediatric trial of severe hypoglycaemia

Ipsen announces positive results from ENGAGE study of Dysport combo with GSC in adults with upper and lower limb spastic hemiparesis

Clovis Oncology acquires rights to FAP-targeted radiopharmaceutical programme from 3B Pharmaceuticals

Cerevel’s tavapadon meets primary endpoint in phase 2 trial in Parkinson’s disease

Graybug Vision initiates clinical trial in macular edema secondary to diabetic macular edema or retinal vein occlusion

Novartis’ Cosentyx meets primary endpoint at Week 16 in PREVENT trial

Concert Pharmaceuticals completes enrollment in second open label trial of CTP-543 in alopecia areata

Pharmaceutical Business review is using cookies

Research & Development

Patient Enrollment

Drug Filing

Manufacturing

Packaging

No data found